Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia

By Iqbal Zafar   Siddiqui Rubina T   Qureshi Javed A   Khalid Ahmad M  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 249-254

Future Medicine

Access to resources Recommend Favorite

Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

By  

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-03 ,pp. : 27-31

Karger

Access to resources Recommend Favorite

Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients

By  

Acta Haematologica, Vol. 127, Iss. 1, 2011-10 ,pp. : 34-42

Karger

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite